Thyrocare Technologies primarily operates in healthcare segment and is primarily involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. On the financial health front, the company looks sound with zero debt in its balance sheet. Currently, the stock trades at 28.5x of its earnings and delivers 32.4% RoCE. The company also pays heavy dividends of ~90%. With concrete business and attractive returns, we recommend BUY on the stock.

Download Full Report View Full Report in Browser